Search details
1.
Effects of PI3K Inhibition on Afucosylated Antibody-Driven FcγRIIIa Events and Phospho-S6 Activity in NK Cells.
J Immunol
; 203(1): 137-147, 2019 07 01.
Article
in English
| MEDLINE | ID: mdl-31092639
2.
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome.
Nat Genet
; 36(3): 288-92, 2004 Mar.
Article
in English
| MEDLINE | ID: mdl-14981519
3.
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
J Med Chem
; 65(24): 16589-16621, 2022 12 22.
Article
in English
| MEDLINE | ID: mdl-36455032
4.
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy.
Cancer Discov
; 12(1): 204-219, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34544753
5.
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Drug Metab Dispos
; 38(9): 1436-42, 2010 Sep.
Article
in English
| MEDLINE | ID: mdl-20538720
6.
Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.
Genetics
; 170(1): 161-71, 2005 May.
Article
in English
| MEDLINE | ID: mdl-15744054
7.
The PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromatase.
Genes Cancer
; 7(3-4): 73-85, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-27382432
8.
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition.
Genes Cancer
; 5(3-4): 113-26, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-25053989
9.
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a ß-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
J Med Chem
; 56(11): 4597-610, 2013 Jun 13.
Article
in English
| MEDLINE | ID: mdl-23662903
10.
Oncogenic ERBB3 mutations in human cancers.
Cancer Cell
; 23(5): 603-17, 2013 May 13.
Article
in English
| MEDLINE | ID: mdl-23680147
11.
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
PLoS One
; 7(5): e36402, 2012.
Article
in English
| MEDLINE | ID: mdl-22570710
12.
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Clin Cancer Res
; 18(22): 6239-48, 2012 Nov 15.
Article
in English
| MEDLINE | ID: mdl-22992516
13.
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Mol Cancer Ther
; 10(12): 2426-36, 2011 Dec.
Article
in English
| MEDLINE | ID: mdl-21998291
14.
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Sci Transl Med
; 2(48): 48ra66, 2010 Sep 08.
Article
in English
| MEDLINE | ID: mdl-20826841
15.
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Cancer Res
; 70(3): 1164-72, 2010 Feb 01.
Article
in English
| MEDLINE | ID: mdl-20103642
16.
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.
Cancer Cell
; 17(4): 362-75, 2010 Apr 13.
Article
in English
| MEDLINE | ID: mdl-20385361
Results
1 -
16
de 16
1
Next >
>>